

Diagnostic Imaging Pathways - Focal Liver Lesion (Investigation)

Population Covered By The Guidance

This pathway provides guidance on imaging in patients with focal liver lesions, dependent on whether the patient has risk factors for primary cancer or metastases or whether the lesion is 'incidental'.

Date reviewed: September 2015

Date of next review: 2017/2018






Published: February 2016

Quick User Guide

Move the mouse cursor over the **PINK** text boxes inside the flow chart to bring up a pop up box with salient points.

Clicking on the **PINK** text box will bring up the full text.

The relative radiation level (RRL) of each imaging investigation is displayed in the pop up box.

| SYMBOL | RRL | EFFECTIVE DOSE RANGE |
|--|------------|-----------------------------|
|  | None | 0 |
|  | Minimal | < 1 millisieverts |
|  | Low | 1-5 mSv |
|  | Medium | 5-10 mSv |
|  | High | >10 mSv |

Pathway Diagram





Image Gallery

Note: These images open in a new page

1



Hepatic Haemangioma

Image 1 (Computed Tomography): Post-contrast images demonstrating initial peripheral enhancement, followed by delayed filling of the lesion with contrast. These features are typical of a haemangioma.

2a



Hepatic Haemangioma

Image 2a, 2b and 2c (Triphasic Computed Tomography): Non-contrast scan (Image 2a) demonstrates a subtle low attenuation lesion in segment 6 of the liver (arrow). There is globular peripheral enhancement of the lesion in the post contrast arterial phase scan (Image 2b) with delayed filling in of the lesion in the portal venous phase (Image 2c).

2b



2c




2d



Image 2d (Ultrasound): Ultrasound scan demonstrating the liver lesion in same patient.


3a



Hepatic Haemangioma

Image 3a (H&E, x2.5): Histological section of a hepatic haemangioma showing variously sized, dilated and congested blood vessels set in a fibrous stroma with residual islands of liver parenchyma.


4a



Hepatic Adenoma

Image 4a and 4b (Computed Tomography): Coronal and axial views demonstrating several enhancing liver lesions.

4b



4c




Image 4c (Ultrasound): Ultrasound scan demonstrating the liver lesions in same patient.

5a



Hepatic Focal Nodular Hyperplasia

Image 5a and 5b (Triphasic Computed Tomography): The arterial phase scan (Image 5a) shows a hyperattenuating nodular lesion (narrow arrow) with the typical central scar (broad arrow) in segment 4 of the liver. On the delayed portal venous phase (Image 5b), the lesion becomes isoattenuating (arrow).

5b



6a




Hepatic Focal Nodular Hyperplasia

Image 6a, 6b, 6c and 6d (Magnetic Resonance Imaging): Gadolinium-enhanced T1-weighted MRI (Image 6a) demonstrates an ill-defined low-signal intensity mass in segment 4 of the liver with intense enhancement in the arterial phase (Image 6b). Minor enhancement persists in the portal




venous phase (Image 6c) and the lesion becomes isointense with enhancement of the central scar (arrow) on the delayed image (Image 6d).



Simple Hepatic Cyst

Image 7 (Ultrasound): Simple-appearing cyst in the left lobe of liver.



Hepatocellular Carcinoma

Image 8a and 8b (Ultrasound): Within segment 6 of the liver, there is an approximately 2cm subcapsular hypoechoic lesion (arrow) which does not demonstrate any increased vascularity.






Image 8c, 8d, 8e and 8f (Triphasic Computed Tomography): CT of the same patient shows a cirrhotic liver with patent hepatic and portal veins as well as ascites. Within segment 6, there is a nodular area which demonstrates slight enhancement corresponding to the lesion identified on ultrasound (arrow). This lesion could represent either a dysplastic cirrhotic nodule or an early hepatocellular carcinoma.



Focal Liver Lesion (Investigation)

Risk factors for non-cystic focal liver lesions

- For hepatocellular carcinoma
 - Positive hepatitis B or C serology
 - Cirrhosis / chronic hepatitis / primary biliary cirrhosis / autoimmune hepatitis
 - Ethnicity (South East Asians: males >40; females >50; Africans >20)
 - Family history of hepatocellular carcinoma
 - Genetic haemochromatosis

- Non-alcoholic steatohepatitis
- Excess alcohol consumption
- For metastatic disease
 - Current or previous extra-hepatic malignancy
- For adenomas
 - Females on oral contraceptive agents or hormonal replacement therapy
 - Males on androgenic steroids
 - Glycogen storage disease (rare)

Liver Lesion (Incidental)

- The great majority of incidentally-detected liver nodules are benign
- Even in patients with known extrahepatic primary malignancy, small liver lesions, if single or very few in number, are more likely to be benign than malignant
- The problem of incidental lesions, in the liver and elsewhere, is an important component of the burgeoning issue of over diagnosis and the potential harming of healthy people
- It is important to distinguish hepatic adenomas (HA) from focal nodular hyperplasia (FNH) as the former can present acutely due to rupture and consequent haemoperitoneum in addition to the risk of malignant transformation up to 10% of these tumours

Hepatocellular Cancer (Surveillance)

- In patients with cirrhosis, the risk of developing hepatocellular carcinoma (HCC) is highest with HCV, in Asians and in more advanced stages of cirrhosis
- Ultrasonography (US) 6 monthly is recommended as the primary surveillance modality
- Survival was significantly better in patients who underwent surveillance
- The earliest identifiable HCCs often show atypical radiological features and these are the very lesions that need to be diagnosed to enable a higher likelihood of cure
- Sensitivity for detecting hepatocellular carcinoma on US varies with the size of the lesion
- The use of serum alpha-fetoprotein (AFP) alone as a surveillance tool is not recommended
- The use of AFP to complement US surveillance is controversial

Hepatocellular Cancer (Suspected)

- In patients at risk of HCC
 - Liver lesions 1cm should undergo further imaging, preferably with MRI with a liver-specific contrast agent
 - Lesions in patients at high risk for HCC showing typical features of HCC on imaging (arterial enhancement and then wash-out) can be treated as HCC without biopsy
 - Biopsy should be reserved for lesions with non-diagnostic appearances on imaging

Focal Liver Lesion (History of Malignancy)

- Even in patients with known extra-hepatic primary malignancy, small liver lesions, if single or very few in number, are more likely to be benign than malignant
- In patients with known or suspected extra-hepatic primary malignancy, imaging is usually a

- combination of ultrasound and CT, dependent on which modality the lesion was initially discovered
- Simple cysts can be confidently diagnosed on US. May detect or characterize other lesions. If US were the patient's primary imaging modality, contrast-enhanced US (CEUS) is a valuable adjunct performed at the same attendance, if available. Otherwise the next step is usually CT scan

Ultrasound (US) ± Contrast-Enhanced Ultrasound (CEUS)

- Ultrasound (US) contrast agents ('microbubbles') comprise an albumen or phospholipid shell containing a stable perfluorocarbon or sulfur hexafluoride gas. They are predominantly blood-pool agents, the encapsulated microbubbles being small enough to pass through pulmonary and systemic circulations after intravenous injection and durable enough to re-circulate for several minutes
- Examination with US contrast is based on the dynamic assessment of macro- and microvasculature of organs and their pathologies. They are, in principle, comparable to the use of contrast agents for CT and MRI with the added advantage of the capability for imaging continuously during the passage of the contrast agent, thereby obtaining what is effectively a dynamic real-time ultrasound angiogram with greater temporal resolution than contrast-enhanced CT or MRI. In addition, quantitative assessment of contrast uptake can be measured by generating Time-Intensity Curves
- CEUS improves diagnostic performance in differentiating HCCs from non-neoplastic nodules in cirrhotic patients compared with baseline ultrasound (16) and, if available, can be recommended as the first diagnostic step when liver lesions are detected on ultrasound surveillance, especially as the procedure can be performed immediately without the need for further attendance or preparation and may therefore avoid further and more expensive examinations
- Advantages of CEUS
 - Ability to assess the contrast enhancement patterns in real time
 - Higher temporal resolution when compared with other imaging modalities
 - Enhancement dynamics of the lesions can be studied quantitatively and qualitatively
 - No predefined scan time points or need to perform bolus tracking
 - Excellent tolerance and safety profiles of ultrasound contrast agents allow for their repeated administrations in the same session when needed
 - Can be given in the presence of renal impairment
 - The imaging can be performed at the same attendance as the ultrasound at which the lesion was discovered, with resultant early reassurance of the patient and his / her doctors in the majority of cases
- Disadvantages of CEUS
 - Operator and body habitus dependent
 - Specificity and sensitivity are reduced in moderately or markedly fatty livers and with deeply positioned lesions
 - Very small focal liver lesions (

Magnetic Resonance Imaging (MRI)

- MRI is more likely to provide a definitive diagnosis than CT and has an important role in characterizing benign lesions
- Usually breath hold T1 and fast spin-echo T2 weighted images are used for the evaluation of a liver nodule
- Gadolinium-enhanced dynamic MRI imaging improves the characterisation of liver lesions



- Images are commonly taken during the
 - Arterial phase (20-30 seconds after administration of contrast) – useful for identifying hyper-vascular lesions
 - Portal venous phase (70-80 seconds after administration of contrast)
- The patterns of enhancement with gadolinium at MRI of various types of liver lesion are similar to those seen with iodinated contrast at CT
- Hepatobiliary (liver-specific) gadolinium contrast agents (gadoteric acid) are increasingly used, which are taken up by normal liver and by lesions containing hepatocytes (such as focal nodular hyperplasia) on delayed phase imaging. The use of the delayed phase of these agents has been shown to increase sensitivity compared to dynamic phases alone. Thus, MRI with these agents is useful for differentiation of FNH and HA
- These agents also have excellent sensitivities for metastases, show a better performance than triple-phase MDCT for the detection of hepatic metastasis, especially for small (<1 cm) lesions
- In the context of suspected metastatic disease MRI is usually reserved for: problem solving / lesion characterization; further liver imaging to detect additional hepatic metastases if surgical intervention is contemplated
- On a per lesion and per patient basis, MRI is the most accurate modality for evaluating colorectal liver metastases, being more sensitive than CT and having a slightly higher sensitivity to PET / CT
- Diffusion-weighted imaging (DWI) at MRI is particularly sensitive for the detection of metastases on a per-lesion basis. However, on its own, without other MRI sequences, it is controversial whether DWI is reliable in distinguishing benign from malignant lesions. In general, DWI should be combined with other MRI sequences for lesion characterization

18F-fluorodeoxyglucose (FDG) Positron Emission Tomography-Computed Tomography (PET-CT)

- Malignant cells characteristically have increased metabolism compared to normal cells, and may be reflected by areas of increased activity on PET-CT scanning
- However, the 18F-PET-avidity of metastatic disease tends to parallel the avidity of the primary tumour, which in turn varies among cancer-type and even within the same cancer type
- The roles of PET-CT in hepatic metastases are as follows
 - Occasional problem solving when diagnosis on other modalities remains uncertain
 - To determine the presence of extra-hepatic metastases in order to avoid hepatic resection in those patients in whom it is otherwise contemplated
 - To monitor disease activity and disease recurrence following treatment
- In recent years it has become possible to perform PET-CT with Somatostatin Receptors labeled with 68-gallium for the detection of neuroendocrine tumours, including carcinoid tumours. This has been shown to be highly accurate
- A further study in patients with neuroendocrine primary tumours also found PET-CT and MRI to be highly accurate

Technetium-99m-labelled Red Blood Cell Scan (99mTc-RBC)

scan)

- Technetium-99m-labelled red blood cell scan has a high specificity and positive predictive value for hepatic haemangiomas but a negative test result does not indicate a diagnosis and therefore further imaging investigation is then required
- Hepatic haemangiomas occur in up to 7% of the population and are the most common benign tumour of the liver
- Some of these do not demonstrate the characteristic CT and ultrasound appearance and can be difficult to distinguish from other causes of a focal liver lesion
- An increase in delayed blood pool activity is typical of a haemangioma and this appearance is rarely seen with other causes of liver nodules
- The test has a limited sensitivity for the detection of small lesions and those located adjacent to the heart or major vessels
- The use of the test is decreasing as a negative scan excludes haemangioma but does not otherwise aid diagnosis

Image-guided Biopsy

- In the absence of risk factors, the role for biopsy in the diagnosis of hepatic incidentalomas is limited as the advances in dynamic imaging techniques are sensitive for diagnosing hepatocellular carcinoma (HCC) in most liver nodules
- The accuracy of percutaneous needle biopsy is around 90% but the risk of needle track tumour implantation following a biopsy of a hepatocellular carcinoma is 2.7% overall
- Thus needle tract seeding of tumour is a justifiable concern especially if such seeding could impact patient survival and also management options. There has been a more liberal approach for liver lesion biopsies in recent years unless transplantation is considered
- Other complications include intraperitoneal haemorrhage, haemobilia, pneumothorax, infection, bile leak, parenchymal bleeding and pericardial tamponade
- This underlines the importance of performing percutaneous needle biopsy only when absolutely necessary or when the information gained is likely to alter the management
- However, in individuals with risk factors for hepatocellular carcinoma
 - Lesions 2 cm) or,
 - Two imaging modalities (for lesions 1-2 cm) and / or,
 - Alpha-fetoprotein is raised, otherwise biopsy is recommended
- Image-guided fine needle aspiration (FNA) is able to distinguish benign from malignant lesion with high accuracy , but less accurate in providing a specific malignant diagnosis

References

Date of literature search: September 2015

The search methodology is available on request. [Email](#)

References are graded from Level I to V according to the Oxford Centre for Evidence-Based Medicine, Levels of Evidence. Download the document

1. Gore RM, Newmark GM, Thakrar KH, Mehta UK, Berlin JW. **Hepatic incidentalomas**. Radiol Clin North Am. 2011;49(2):291-322. (Review article). [View the reference](#)
2. Moynihan R, Doust J, Henry D. **Preventing overdiagnosis: how to stop harming the healthy**. BMJ. 2012;344:e3502. (Level III evidence). [View the reference](#)
3. Schillaci O, Danieli R, Manni C, Capocchetti F, Simonetti G. **Technetium-99m-labelled red blood cell imaging in the diagnosis of hepatic haemangiomas: the role of SPECT/CT with a hybrid camera**. Eur J Nucl Med Mol Imaging. 2004;34:1011-5. (Level III evidence). [View the reference](#)
4. Klein D, Jenett M, Gassel HJ, et al. **Quantitative dynamic contrast - enhanced sonography of hepatic tumors**. Eur Radiol. 2004;14:1082-91. (Level III evidence). [View the reference](#)
5. Seitz K, Strobel D, Bernatik T, Blank W, Friedrich-Rust M, Herbay A, et al. **Contrast-Enhanced Ultrasound (CEUS) for the characterization of focal liver lesions - prospective comparison in clinical practice: CEUS vs CT (DEGUM multicenter trial). Parts of this manuscript were presented at the Ultrasound Dreilandertreffen 2008, Davos**. Ultraschall Med. 2009;30(4):383-9. (Level II evidence). [View the reference](#)
6. Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolsøe CP, et al. **Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver – update 2012**. Ultraschall in Med. 2013;34(1):11-29. (Guideline). [View the reference](#)
7. Sporea I, Martie A, Bota S, Sirli R, Popescu A, Danila M. **Characterization of focal liver lesions using contrast enhanced ultrasound as a first line method: a large monocentric experience**. J Gastrointestin Liver Dis. 2014;23(1):57-63. (Level III evidence). [View the reference](#)
8. Won SY, Singh N, Lim BG, Stella D, Gibson R. **Hepatic contrast-enhanced ultrasound: impact of its introduction in the Australian context**. J Med Imaging Radiat Oncol. 2014;58(1):38-45. (Level III evidence). [View the reference](#)
9. Whitney WS, Herfkens RJ, Jeffrey RB, et al. **Dynamic breath-hold multiplanar spoiled gradient-recalled MR imaging with gadolinium enhancement for differentiating hepatic haemangiomas from malignancies at 1.5T**. Radiology. 1993;189:863-70. (Level III evidence). [View the reference](#)
10. Boutros C, Katz SC, Espat NJ. **Management of an incidental liver mass**. Surg Clin North Am. 2010;90(4):699-718. (Review article). [View the reference](#)
11. Buell JF, Tranchart H, Cannon R, Dagher I. **Management of benign hepatic tumors**. Surg Clin North Am. 2010;90(4):719-35. (Review article). [View the reference](#)
12. Leslie DF, Johnson CD, MacCarty RL, et al. **Single-pass CT of hepatic tumors: value of globular enhancement in distinguishing hemangiomas from hypervascular metastases**. AJR Am J Roentgenol. 1995;165:1403-6. (Level III evidence). [View the reference](#)
13. Yamashita Y, Ogata I, Urata J, et al. **Cavernous hemangioma of the liver: pathologic correlation with dynamic CT findings**. Radiology. 1997;203:121-6. (Level III evidence). [View the reference](#)
14. Royal HD, Brown ML, Drum DE, et al. **Procedure guideline for hepatic and splenic imaging. Society of Nuclear Medicine**. J Nucl Med. 1998;39:1114-6. (Guideline). [View the reference](#)
15. Federle MP, Filly RA, Moss AA. **Cystic hepatic neoplasms: complementary roles of CT and sonography**. AJR Am J Roentgenol. 1981;136:345-8. (Level III evidence). [View the reference](#)

[reference](#)

16. Margolis NE, Shaver CM, Rosenkrantz AB. **Indeterminate liver and renal lesions: comparison of computed tomography and magnetic resonance imaging in providing a definitive diagnosis and impact on recommendations for additional imaging.** J Comput Assist Tomogr. 2013;37(6):882-6. (Level III evidence). [View the Reference](#)
17. Cogley JR, Miller FH. **MR imaging of benign focal liver lesions.** Radiol Clin North Am. 2014;52(4):657-82. (Review article). [View the reference](#)
18. Rode A, Bancel B, Douek P, et al. **Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver.** J Comput Assist Tomogr. 2001;25:327-36. (Level II evidence). [View the reference](#)
19. Purysko AS, Remer EM, Coppa CP, Obuchowski NA, Schneider E, Veniero JC. **Characteristics and distinguishing features of hepatocellular adenoma and focal nodular hyperplasia on gadoxetate disodium-enhanced MRI.** AJR Am J Roentgenol. 2012;198(1):115-23. (Level III evidence). [View the reference](#)
20. Harvey CJ, Albrecht T. **Ultrasound of focal liver lesions.** Eur Radiol. 2001;11:1578-93. (Review article). [View the reference](#)
21. Grieser C, Steffen IG, Seehofer D, Kramme IB, Uktolseya R, Scheurig-Muenkler C, et al. **Histopathologically confirmed focal nodular hyperplasia of the liver: gadoxetic acid-enhanced MRI characteristics.** Magn Reson Imaging. 2013;31(5):755-60. (Level III evidence). [View the reference](#)
22. Jang HJ, Kim TK, Lim HK, et al. **Hepatic hemangioma: atypical appearances on CT, MR imaging, and sonography.** AJR Am J Roentgenol. 2003;180:135-41. (Review article). [View the reference](#)
23. Ziessman HA, Silverman PM, Patterson J, et al. **Improved detection of small cavernous hemangiomas of the liver with high-resolution three-headed SPECT.** J Nucl Med. 1991;32:2086-91. (Level III evidence). [View the reference](#)
24. Birnbaum BA, Weinreb JC, Megibow AJ, et al. **Definitive diagnosis of hepatic hemangiomas: MR imaging versus Tc-99m-labeled red blood cell SPECT.** Radiology. 1990;176:95-101. (Level III evidence). [View the reference](#)
25. Wee A. **Fine-needle aspiration biopsy of hepatocellular carcinoma and related hepatocellular nodular lesions in cirrhosis: controversies, challenges, and expectations.** Patholog Res Int. 2011;2011:17. (Review article). [View the reference](#)
26. Torzilli G, Minagawa M, Takayama T, Inoue K, Hui A-M, Kubota K, et al. **Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy.** Hepatology. 1999;30(4):889-93. (Level II evidence). [View the reference](#)
27. Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF. **Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis.** Gut. 2008;57(11):1592-6. (Level II/III evidence). [View the reference](#)
28. Caturelli E, Solmi L, Anti M, et al. **Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study.** Gut. 2004;53:1356-62. (Level II evidence). [View the reference](#)
29. Chang S, Kim SH, Lim HK, Lee WJ, Choi D, Lim JH. **Needle tract implantation after sonographically guided percutaneous biopsy of hepatocellular carcinoma: evaluation of doubling time, frequency, and features on CT.** AJR Am J Roentgenol. 2005; 185:400-5. (Level III evidence). [View the reference](#)
30. Fattovich G, Stroffolini T, Zagni I, Donato F. **Hepatocellular carcinoma in cirrhosis: incidence and risk factors.** Gastroenterology. 2004;127(5 Suppl 1):S35-50. (Review article). [View the reference](#)
31. Bruix J, Sherman M. **Management of hepatocellular carcinoma: an update.** Hepatology. 2011;53(3):1020-2. (Review article). [View the reference](#)

32. European Association for the Study of the Liver EOfRaToC. **EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.** J Hepatol. 2012;56(4):908-43. (Guidelines). [View the reference](#)
33. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. **Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.** Hepatol Int. 2010;4(2):439-74. (Guidelines). [View the reference](#)
34. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, et al. **Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.** Dig Dis. 2011;29(3):339-64. (Guidelines). [View the reference](#)
35. Bruix J, Sherman M. **Management of hepatocellular carcinoma.** Hepatology. 2005;42(5):1208-36. (Guidelines). [View the reference](#)
36. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. **Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.** J Hepatol. 2001;35(3):421-30. (Review article). [View the reference](#)
37. Leoni S, Piscaglia F, Golfieri R, Camaggi V, Vidili G, Pini P, et al. **The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria.** Am J Gastroenterol. 2010;105(3):599-609. (Level II evidence). [View the reference](#)
38. Della Corte C, Colombo M. **Surveillance for hepatocellular carcinoma.** Semin Oncol. 2012;39(4):384-98. (Review article). [View the reference](#)
39. Zhang BH, Yang BH, Tang ZY. **Randomized controlled trial of screening for hepatocellular carcinoma.** J Cancer Res Clin Oncol. 2004;130(7):417-22. (Level II evidence). [View the reference](#)
40. Kansagara D, Papak J, Pasha AS, O'Neil M, Freeman M, Relevo R, et al. **Screening for hepatocellular carcinoma in chronic liver disease: a systematic review.** Ann Intern Med. 2014;161(4):261-9. (Level I/II evidence). [View the reference](#)
41. Trevisani F, Cantarini MC, Labate AM, De Notariis S, Rapaccini G, Farinati F, et al. **Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival.** Am J Gastroenterol. 2004;99(8):1470-6. (Level III evidence). [View the reference](#)
42. Trevisani F, De Notariis S, Rapaccini G, Farinati F, Benvegna L, Zoli M, et al. **Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience).** Am J Gastroenterol. 2002;97(3):734-44. (Level III evidence). [View the reference](#)
43. Wong LL, Limm WM, Severino R, Wong LM. **Improved survival with screening for hepatocellular carcinoma.** Liver Transpl. 2000;6(3):320-5. (Level III evidence). [View the reference](#)
44. Yu EW, Chie WC, Chen TH. **Does screening or surveillance for primary hepatocellular carcinoma with ultrasonography improve the prognosis of patients?** Cancer J. 2004;10(5):317-25.
45. Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. **Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience.** Hepatology. 2000;31(2):330-5. (Level III evidence). [View the reference](#)
46. Midorikawa Y, Takayama T, Shimada K, Nakayama H, Higaki T, Moriguchi M, et al. **Marginal survival benefit in the treatment of early hepatocellular carcinoma.** J Hepatol. 2013;58(2):306-11. (Level III evidence). [View the reference](#)
47. Edenvik P, Davidsdottir L, Oksanen A, Isaksson B, Hultcrantz R, Stal P. **Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from**

- clinical practice?** Liver Int. 2015;35(7):1862-71. (Level III evidence). [View the reference](#)
48. Sherman M. **The radiological diagnosis of hepatocellular carcinoma.** Am J Gastroenterol. 2010;105(3):610-2. (Level IV/V evidence). [View the reference](#)
49. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, et al. **Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis.** Aliment Pharmacol Ther. 2009;30(1):37-47. (Level I evidence). [View the reference](#)
50. Chou R, Cuevas C, Fu R, Devine B, Wasson N, Ginsburg A, et al. **Imaging techniques for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis.** Ann Intern Med. 2015;162(10):697-711. (Level I evidence). [View the reference](#)
51. Pocha C, Dieperink E, McMaken KA, Knott A, Thuras P, Ho SB. **Surveillance for hepatocellular cancer with ultrasonography vs computed tomography: a randomised study.** Aliment Pharmacol Ther. 2013;38(3):303-12. (Level II/III evidence). [View the reference](#)
52. Bolondi L, Cillo U, Colombo M, Craxi A, Farinati F, Giannini EG, et al. **Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma.** Dig Liver Dis. 2013;45(9):712-23. (Guidelines). [View the reference](#)
53. Barreiros AP, Piscaglia F, Dietrich CF. **Contrast enhanced ultrasound for the diagnosis of hepatocellular carcinoma (HCC): comments on AASLD guidelines.** J Hepatol. 2012;57(4):930-2. (Level IV/V evidence). [View the reference](#)
54. Sangiovanni A, Manini MA, Iavarone M, Romeo R, Forzenigo LV, Fraquelli M, et al. **The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis.** Gut. 2010;59(5):638-44. (Level III evidence). [View the reference](#)
55. Serste T, Barrau V, Ozenne V, Vullierme MP, Bedossa P, Farges O, et al. **Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy.** Hepatology. 2012;55(3):800-6. (Level III evidence). [View the reference](#)
56. Tanaka H, Iijima H, Nouse K, Aoki N, Iwai T, Takashima T, et al. **Cost-effectiveness analysis on the surveillance for hepatocellular carcinoma in liver cirrhosis patients using contrast-enhanced ultrasonography.** Hepatol Res. 2012;42(4):376-84. (Level III evidence). [View the reference](#)
57. Xu HX, Lu MD, Liu LN, Zhang YF, Guo LH, Xu JM, et al. **Discrimination between neoplastic and non-neoplastic lesions in cirrhotic liver using contrast-enhanced ultrasound.** Br J Radiol. 2012;85(1018):1376-84. (Level III evidence). [View the reference](#)
58. Dumitrescu CI, Gheonea IA, Sandulescu L, Surlin V, Saftoiu A, Dumitrescu D. **Contrast enhanced ultrasound and magnetic resonance imaging in hepatocellular carcinoma diagnosis.** Med Ultrason. 2013;15(4):261-7. (Level IV evidence). [View the reference](#)
59. Webb GJ, Wright KV, Harrod EC, Gorard DA, Collier JD, Evans AK. **Surveillance for hepatocellular carcinoma in a mixed-aetiology UK cohort with cirrhosis: does alpha-fetoprotein still have a role?** Clin Med. 2015;15(2):139-44. (Level III/IV evidence). [View the reference](#)
60. El-Serag HB, Kanwal F. **Alpha-fetoprotein in hepatocellular carcinoma surveillance: mend it but do not end it.** Clin Gastroenterol Hepatol. 2013;11(4):441-3. (Level IV/V evidence). [View the reference](#)
61. Chang TS, Wu YC, Tung SY, Wei KL, Hsieh YY, Huang HC, et al. **Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis.** Am J Gastroenterol. 2015;110(6):836-44. (Level III evidence). [View the reference](#)

62. Huang TS, Shyu YC, Turner R, Chen HY, Chen PJ. **Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol.** Syst Rev. 2013;2(2):37. (Level I/II evidence). [View the reference](#)
63. Witjes CD, van Aalten SM, Steyerberg EW, Borsboom GJ, de Man RA, Verhoef C, et al. **Recently introduced biomarkers for screening of hepatocellular carcinoma: a systematic review and meta-analysis.** Hepatol Int. 2013;7(1):59-64. (Level I evidence). [View the reference](#)
64. Giannini EG, Cucchetti A, Erroi V, Garuti F, Odaldi F, Trevisani F. **Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it?** World J Gastroenterol. 2013;19(47):8808-21. (Guidelines). [View the reference](#)
65. Ronot M, Vilgrain V. **Hepatocellular carcinoma: diagnostic criteria by imaging techniques.** Best Pract Res Clin Gastroenterol. 2014;28(5):795-812. (Review article). [View the reference](#)
66. Lee YJ, Lee JM, Lee JS, Lee HY, Park BH, Kim YH, et al. **Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis.** Radiology. 2015;275(1):97-109. (Level I/II evidence). [View the reference](#)
67. Numata K, Fukuda H, Nihonmatsu H, Kondo M, Nozaki A, Chuma M, et al. **Use of vessel patterns on contrast-enhanced ultrasonography using a perflubutane-based contrast agent for the differential diagnosis of regenerative nodules from early hepatocellular carcinoma or high-grade dysplastic nodules in patients with chronic liver disease.** Abdom Imaging. 2015;40(7):2372-83. (Level III evidence). [View the reference](#)
68. D'Onofrio M, Crosara S, De Robertis R, Canestrini S, Mucelli RP. **Contrast-enhanced ultrasound of focal liver lesions.** AJR Am J Roentgenol. 2015;205(1):W56-66. (Review article). [View the reference](#)
69. Sirlin CB, Hussain HK, Jonas E, Kanematsu M, Min Lee J, Merkle EM, et al. **Consensus report from the 6th international forum for liver MRI using gadoxetic acid.** J Magn Reson Imaging. 2014;40(3):516-29. (Guidelines). [View the reference](#)
70. Junqiang L, Yinzhong W, Li Z, Shunlin G, Xiaohui W, Yanan Z, et al. **Gadoxetic acid disodium (Gd-EOBDDTPA) enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: a meta-analysis.** J Magn Reson Imaging. 2014;39(5):1079-87. (Level I/II evidence). [View the reference](#)
71. Zech CJ, Bartolozzi C, Bioulac-Sage P, Chow PK, Forner A, Grazioli L, et al. **Consensus report of the Fifth International Forum for Liver MRI.** AJR Am J Roentgenol. 2013;201(1):97-107. (Guidelines). [View the reference](#)
72. Kwon HJ, Byun JH, Kim JY, Hong GS, Won HJ, Shin YM, et al. **Differentiation of small (≤ 2 cm) hepatocellular carcinomas from small benign nodules in cirrhotic liver on gadoxetic acid-enhanced and diffusion-weighted magnetic resonance images.** Abdom Imaging. 2015;40(1):64-75. (Level III evidence). [View the reference](#)
73. Tsurusaki M, Sofue K, Isoda H, Okada M, Kitajima K, Murakami T. **Comparison of gadoxetic acid-enhanced magnetic resonance imaging and contrast-enhanced computed tomography with histopathological examinations for the identification of hepatocellular carcinoma: a multicenter phase III study.** J Gastroenterol. 2016;51(1):71-9. (Level II/III evidence). [View the reference](#)
74. Inchingolo R, De Gaetano AM, Curione D, Ciresa M, Miele L, Pompili M, et al. **Role of diffusion-weighted imaging; apparent diffusion coefficient and correlation with hepatobiliary phase findings in the differentiation of hepatocellular carcinoma from dysplastic nodules in cirrhotic liver.** Eur Radiol. 2015;25(4):1087-96. (Level III evidence). [View the reference](#)
75. Sutherland T, Steele E, van Tonder F, Yap K. **Solid focal liver lesion characterisation**

- with apparent diffusion coefficient ratios.** J Med Imaging Radiat Oncol. 2014;58(1):32-7. (Level III evidence). [View the reference](#)
76. Wu LM, Xu JR, Lu Q, Hua J, Chen J, Hu J. **A pooled analysis of diffusion-weighted imaging in the diagnosis of hepatocellular carcinoma in chronic liver diseases.** J Gastroenterol Hepatol. 2013;28(2):227-34. (Level II/III evidence). [View the reference](#)
77. Li Y, Chen Z, Wang J. **Differential diagnosis between malignant and benign hepatic tumors using apparent diffusion coefficient on 1.5-T MR imaging: a meta analysis.** Eur J Radiol. 2012;81(3):484-90. (Level II evidence). [View the reference](#)
78. Sherman M, Bruix J. **Biopsy for liver cancer: how to balance research needs with evidence-based clinical practice.** Hepatology. 2015;61(2):433-6. (Level IV/V evidence). [View the reference](#)
79. Chhieng DC. **Fine needle aspiration biopsy of liver - an update.** World J Surg Oncol. 2004;2:5. (Review article). [View the reference](#)
80. Borhani AA, Wiant A, Heller MT. **Cystic hepatic lesions: a review and an algorithmic approach.** AJR Am J Roentgenol. 2014;203(6):1192-204. (Review article). [View the reference](#)
81. Sporea I, Badea R, Martie A, Sirli R, Socaciu M, Popescu A, et al. **Contrast enhanced ultrasound for the characterization of focal liver lesions.** Med Ultrason. 2011;13(1):38-44. (Level III evidence). [View the reference](#)
82. Ryu SW, Bok GH, Jang JY, Jeong SW, Ham NS, Kim JH, et al. **Clinically useful diagnostic tool of contrast enhanced ultrasonography for focal liver masses: comparison to computed tomography and magnetic resonance imaging.** Gut Liver. 2014;8(3):292-7. (Level III evidence). [View the reference](#)
83. Westwood M, Joore M, Grutters J, Redekop K, Armstrong N, Lee K, et al. **Contrast-enhanced ultrasound using SonoVue(R) (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis.** Health Technol Assess. 2013;17(16):1-243. (Level II/III evidence). [View the reference](#)
84. Mainenti PP, Romano F, Pizzuti L, Segreto S, Storto G, Mannelli L, et al. **Non-invasive diagnostic imaging of colorectal liver metastases.** World J Radiol. 2015;7(7):157-69. (Review article). [View the reference](#)
85. Niekel MC, Bipat S, Stoker J. **Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment.** Radiology. 2010;257(3):674-84. (Level I/II evidence). [View the reference](#)
86. Deng J, Tang J, Shen N. **Meta-analysis of diagnosis of liver metastatic cancers: comparison of (18) FDG PET-CT and gadolinium-enhanced MRI.** J Med Imaging Radiat Oncol. 2014;58(5):532-7. (Level I/II evidence). [View the reference](#)
87. Fu GL, Du Y, Zee CS, Yang HF, Li Y, Duan RG, et al. **Gadobenate dimeglumine-enhanced liver magnetic resonance imaging: value of hepatobiliary phase for the detection of focal liver lesions.** J Comput Assist Tomogr. 2012;36(1):14-9. (Level III evidence). [View the reference](#)
88. Chen L, Zhang J, Zhang L, Bao J, Liu C, Xia Y, et al. **Meta-analysis of Gadoteric acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance imaging for the detection of liver metastases.** PLoS ONE. 2012;7(11):e48681. (Level I evidence). [View the reference](#)
89. Kim YK, Park G, Kim CS, Yu HC, Han YM. **Diagnostic efficacy of gadoteric acid-enhanced MRI for the detection and characterisation of liver metastases: comparison with multidetector-row CT.** Radiol. 2012;85(1013):539-47. (Level III evidence). [View the reference](#)

90. Bottcher J, Hansch A, Pfeil A, Schmidt P, Malich A, Schneeweiss A, et al. **Detection and classification of different liver lesions: comparison of Gd-EOB-DTPA-enhanced MRI versus multiphasic spiral CT in a clinical single centre investigation.** Eur J Radiol. 2013;82(11):1860-9. (Level III evidence). [View the reference](#)
91. Lee KH, Lee JM, Park JH, Kim JH, Park HS, Yu MH, et al. **MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent gadoxetic acid.** Korean J Radiol. 2013;14(6):894-904. (Level II/III evidence). [View the reference](#)
92. Eiber M, Fingerle AA, Brugel M, Gaa J, Rummeny EJ, Holzapfel K. **Detection and classification of focal liver lesions in patients with colorectal cancer: retrospective comparison of diffusion-weighted MR imaging and multi-slice CT.** Eur J Radiol. 2012;81(4):683-91. (Level III evidence). [View the reference](#)
93. Chen Z-G, Xu L, Zhang S-W, Huang Y, Pan R-H. **Lesion discrimination with breath-hold hepatic diffusion-weighted imaging: a meta-analysis.** World J Gastroenterol. 2015;21(5):1621-7. (Level I evidence). [View the reference](#)
94. Holzapfel K, Eiber MJ, Fingerle AA, Bruegel M, Rummeny EJ, Gaa J. **Detection, classification, and characterization of focal liver lesions: value of diffusion-weighted MR imaging, gadoxetic acid-enhanced MR imaging and the combination of both methods.** Abdom Imaging. 2012;37(1):74-82. (Level III evidence). [View the reference](#)
95. Tajima T, Akahane M, Takao H, Akai H, Kiryu S, Imamura H, et al. **Detection of liver metastasis: is diffusion-weighted imaging needed in Gd-EOB-DTPA-enhanced MR imaging for evaluation of colorectal liver metastases?** Jpn J Radiol. 2012;30(8):648-58. (Level II/III evidence). [View the reference](#)
96. Wu LM, Hu J, Gu HY, Hua J, Xu JR. **Can diffusion-weighted magnetic resonance imaging (DW-MRI) alone be used as a reliable sequence for the preoperative detection and characterisation of hepatic metastases? A meta-analysis.** Eur J Cancer. 2013;49(3):572-84. (Level I evidence). [View the reference](#)
97. Wei C, Tan J, Xu L, Juan L, Zhang SW, Wang L, et al. **Differential diagnosis between hepatic metastases and benign focal lesions using DWI with parallel acquisition technique: a meta-analysis.** Tumour Biol. 2015;36(2):983-90. (Level I evidence). [View the reference](#)
98. Maffione AM, Lopci E, Bluemel C, Giammarile F, Herrmann K, Rubello D. **Diagnostic accuracy and impact on management of (18)F-FDG PET and PET/CT in colorectal liver metastasis: a meta-analysis and systematic review.** Eur J Nucl Med Mol Imaging. 2015;42(1):152-63. (Level I evidence). [View the reference](#)
99. Yang J, Kan Y, Ge BH, Yuan L, Li C, Zhao W. **Diagnostic role of gallium-68 DOTATOC and gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis.** Acta Radiol. 2014;55(4):389-98. (Level I evidence). [View the reference](#)
100. Geijer H, Breimer LH. **Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis.** Eur J Nucl Med Mol Imaging. 2013;40(11):1770-80. (Level I evidence). [View the reference](#)
101. Armbruster M, Zech CJ, Sourbron S, Ceelen F, Auernhammer CJ, Rist C, et al. **Diagnostic accuracy of dynamic gadoxetic-acid-enhanced MRI and PET/CT compared in patients with liver metastases from neuroendocrine neoplasms.** J Magn Reson Imaging. 2014;40(2):457-66. (Level II/III evidence). [View the reference](#)
102. McGahan JP, Bishop J, Webb J, Howell L, Torok N, Lamba R, et al. **Role of FNA and core biopsy of primary and metastatic liver disease.** Int J Hepatol. 2013;2013:174103. (Level III evidence). [View the reference](#)

Information for Consumers



| Information from this website | Information from the Royal Australian and New Zealand College of Radiologists' website |
|--|---|
| <p>Radiation Risks of X-rays and Scans</p> <p>Computed Tomography (CT)</p> <p>Magnetic Resonance Imaging (MRI)</p> <p>Ultrasound</p> | <p>Computed Tomography (CT)</p> <p>Contrast Medium (Gadolinium versus Iodine)</p> <p>Gadolinium Contrast Medium</p> <p>Iodine-Containing Contrast Medium</p> <p>Magnetic Resonance Imaging (MRI)</p> <p>Radiation Risk of Medical Imaging During Pregnancy</p> <p>Radiation Risk of Medical Imaging for Adults and Children</p> <p>Ultrasound</p> <p>Nuclear Medicine</p> |

Copyright

© Copyright 2015, Department of Health Western Australia. All Rights Reserved. This web site and its content has been prepared by The Department of Health, Western Australia. The information contained on this web site is protected by copyright.

Legal Notice

Please remember that this leaflet is intended as general information only. It is not definitive and The Department of Health, Western Australia can not accept any legal liability arising from its use. The information is kept as up to date and accurate as possible, but please be warned that it is always subject to change

File Formats

Some documents for download on this website are in a Portable Document Format (PDF). To read these files you might need to download Adobe Acrobat Reader.



[Legal Matters](#)